SSX2

Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells

Retrieved on: 
Wednesday, May 31, 2023
Lymphoma, Baylor, Antigen, Marker, Probability, CD19, Vasileiou, Chong, TAA, Neoplasm, The New England Journal of Medicine, Drug discovery, Clinical trial, SSX2, PRAME, CAR, Patient, Standard of care, WT-1, Growth, FDA, Therapy, IND, Safety, Bone marrow, Vaccine, Pharmaceutical industry, Survivin, Research

The multiTAA-specific T cell product used in the TACTAL study was directed against five antigens and showed more durable clinical responses.

Key Points: 
  • The multiTAA-specific T cell product used in the TACTAL study was directed against five antigens and showed more durable clinical responses.
  • Prior to starting the clinical trial Marker assessed the killing capacity of MT-601 in vitro in a lymphoma cell line and demonstrated that MT-601 kills lymphoma cells regardless of their CD19 expression levels.
  • Data from a lymphoma cell line utilizing this model demonstrated that MT-601 inhibited growth of lymphoma cells as well as the growth of CD19 CAR resistant lymphoma cells,” said Eric A. Smith, Ph.D., Director of Research and Development at Marker Therapeutics.
  • While the CAR T cells significantly controlled lymphoma cell growth, we observed that 3 weeks after the start of anti-CD19 CAR T cell administration, a population of lymphoma cells that were resistant to CD19 CAR T cell administration started to grow.

Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Pancreatic Cancer

Retrieved on: 
Wednesday, January 19, 2022
Survival, Trial of the century, American Society of Clinical Oncology, Patient, Technology, Antigen, Clinical trial, Orphan Drug Act of 1983, Degenerative disease, Population, Toxic epidermal necrolysis, NASDAQ, Marker, CEO, GLOBE, Baylor College of Medicine, AML, Society, IND, Pancreatic cancer, WT1, Lymphatic system, Marketing, Therapy, Company, United, Orphan drug, ASCO, Cancer, Neoplasm, Blood, PRAME, FDA, TCR, SSX2, Baylor University, NY-ESO-1, Pharmaceutical industry, Vaccine, Survivin

The FDAs orphan drug designation underscores MT-601s potential as a treatment for pancreatic cancer, a cancer typically diagnosed at an incurable advanced stage with a total overall 5-year survival rate of 10%, said Peter L. Hoang, President & CEO of Marker Therapeutics.

Key Points: 
  • The FDAs orphan drug designation underscores MT-601s potential as a treatment for pancreatic cancer, a cancer typically diagnosed at an incurable advanced stage with a total overall 5-year survival rate of 10%, said Peter L. Hoang, President & CEO of Marker Therapeutics.
  • Marker developed MT-601, a new product targeting six tumor-associated antigens (PRAME, NY-ESO-1, Survivin, MAGE-A4, SSX2, WT1) highly expressed in pancreatic cancer.
  • The Company plans to file an Investigational New Drug Application (IND) for MT-601 for the treatment of pancreatic cancer in 2022.
  • The granting of an orphan designation request does not alter the standard regulatory requirements and process for obtaining marketing approval.